University of Kentucky College of Pharmacy, Lexington, KY, USA.
Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA.
BMC Geriatr. 2023 Mar 10;23(1):137. doi: 10.1186/s12877-023-03876-4.
Polypharmacy and inappropriate medications may be a modifiable risk factor for Alzheimer's Disease and Related Dementias (ADRD). Medication therapy management (MTM) interventions may mitigate medication-induced cognitive dysfunction and delay onset of symptomatic impairment. The objective of the current study is to describe an MTM protocol for a patient-centered team intervention (pharmacist and non-pharmacist clinician) in a randomized controlled trial (RCT) directed at delaying the symptomatic onset of ADRD.
Community dwelling adults 65 + years, non-demented, using ≥ 1 potentially inappropriate medications (PIM) were enrolled in an RCT to evaluate the effect of an MTM intervention on improving medication appropriateness and cognition (NCT02849639). The MTM intervention involved a three-step process: (1) pharmacist identified potential medication-related problems (MRPs) and made initial recommendations for prescribed and over-the-counter medications, vitamins, and supplements; (2) study team reviewed all initial recommendations together with the participants, allowing for revisions prior to the finalized recommendations; (3) participant responses to final recommendations were recorded. Here, we describe initial recommendations, changes during team engagement, and participant responses to final recommendations.
Among the 90 participants, a mean 6.7 ± 3.6 MRPs per participant were reported. Of the 259 initial MTM recommendations made for the treatment group participants (N = 46), 40% percent underwent revisions in the second step. Participants reported willingness to adopt 46% of final recommendations and expressed need for additional primary care input in response to 38% of final recommendations. Willingness to adopt final recommendations was highest when therapeutic switches were offered and/or with anticholinergic medications.
The evaluation of modifications to MTM recommendations demonstrated that pharmacists' initial MTM recommendations often changed following the participation in the multidisciplinary decision-making process that incorporated patient preferences. The team was encouraged to see a correlation between engaging patients and a positive overall response towards participant acceptance of final MTM recommendations.
Study registration number: clinicaltrial.gov NCT02849639 registered on 29/07/2016.
多种药物治疗和不适当的药物可能是阿尔茨海默病和相关痴呆症(ADRD)的可改变的危险因素。药物治疗管理(MTM)干预措施可能减轻药物引起的认知功能障碍并延迟有症状的损害的发生。本研究的目的是描述一种针对以患者为中心的团队干预(药剂师和非药剂师临床医生)的 MTM 方案,该方案是一项针对延迟 ADRD 症状发作的随机对照试验(RCT)。
65 岁及以上、无痴呆、使用≥1 种潜在不适当药物(PIM)的社区居住成年人参加了一项 RCT,以评估 MTM 干预对改善药物适宜性和认知的效果(NCT02849639)。MTM 干预涉及三个步骤:(1)药剂师确定潜在的药物相关问题(MRPs),并对处方和非处方药物、维生素和补充剂提出初步建议;(2)研究团队与参与者一起审查所有初始建议,在最终建议之前允许进行修订;(3)记录参与者对最终建议的反应。在这里,我们描述了初始建议、团队参与过程中的变化以及参与者对最终建议的反应。
在 90 名参与者中,报告了每位参与者平均 6.7±3.6 个 MRPs。在为治疗组参与者(N=46)提出的 259 项初始 MTM 建议中,40%的建议在第二步进行了修订。参与者表示愿意采纳 46%的最终建议,并表示需要额外的初级保健投入,以回应 38%的最终建议。当提供治疗性药物转换和/或抗胆碱能药物时,最终建议的采纳意愿最高。
对 MTM 建议的修改进行评估表明,药剂师的初始 MTM 建议在参与纳入患者偏好的多学科决策过程后往往会发生变化。团队鼓励看到参与患者与患者对最终 MTM 建议的接受度的整体积极反应之间的相关性。
研究注册号:clinicaltrial.gov NCT02849639,于 2016 年 7 月 29 日注册。